Lepu Medical(300003)2025-01-24 11:08Financial Outlook - The company expects a net profit attributable to shareholders of between 265 million and 395 million yuan for 2024, a decrease of 68.61% to 78.94% compared to the previous year[2]. Business Performance - The core cardiovascular interventional business achieved double-digit revenue growth, while the pharmaceutical segment saw a significant decline in revenue due to inventory clearance in retail channels[4]. - The retail channel inventory clearance is nearly complete, with a significant improvement in sales data, indicating steady growth potential for the pharmaceutical segment in 2025[6]. Strategic Initiatives - The company plans to recognize impairment provisions for emergency product-related inventory and goodwill[5]. - The company successfully registered several new products, including VessCrack™ and RF-Lance®, which are expected to support future stable development in the cardiovascular interventional business[6]. - The company has consolidated Shanghai Minwei Bio, with several candidate drugs receiving clinical trial approvals, which will drive the transformation of its pharmaceutical business[7].